SYSTEMIC MANAGEMENT OF LOCALIZED ENDOMETRIAL CANCER: NEWS AND PERSPECTIVES

Abstract

The therapeutic approach of localized endometrial cancer is mainly based on surgery, combined with adjuvant treatment adapted to the risk of recurrence, which may combine brachytherapy, external beam radiotherapy, chemotherapy and chemoradiotherapy.
The assessment of this risk takes into account clinical and histological prognostic criteria, as well as the molecular characteristics of the tumour as defined by the TCGA classification. When indicated, current adjuvant systemic treatment of endometrial cancer is based mainly on platinum-based chemotherapy, possibly following the PORTEC-3 regimen (chemotherapy and chemoradiotherapy). While the prognostic value of the molecular classification of endometrial cancer is well established, its theranostic impact is the cornerstone of current adjuvant clinical trials. The identification of new biomarkers, predictive of the efficacy of targeted therapies, is also a major focus, without neglecting the role of supportive care.